Abeona Therapeutics Inc vs Okta, Inc. — how do they compare? Abeona Therapeutics Inc trades at $7.42 (market cap $421.19M), while Okta, Inc. trades at $152.1 (market cap $26.13B). The key difference: Okta, Inc. is far larger — about 62× Abeona Therapeutics Inc's market cap. Which is the better fit depends on your goals.
| ABEO | OKTA | |
|---|---|---|
Market Cap | $421.19M | $26.13B |
Sector | Health | Technology |
52-Week High | $7.45 | $154.62 |
52-Week Low | $4.17 | $62.93 |
Enterprise Value | $276.10M | $23.95B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
OKTA trades at $150.77, up 1.65% today, with a bullish technical signal from moving averages and strong quarterly earnings beats. Revenue grew to $2.61B in 2025, achieving a net income of $28M after recent losses. The company maintains a 77.44% gross margin and positive operating cash flow of $750M, supported by strategic acquisitions like Permiso Security for AI threat defense.
Outlook remains positive with 72.55% analyst buy ratings and a consensus price target of $129.71, though high valuation ratios (P/E 108.93) and overbought RSI levels near 76.86 pose risks. Key catalysts include Q2 2026 earnings on August 26, 2026, and growth in cybersecurity demand.
Trailing returns across standard periods
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →